Formulary monograph
SKY-0515
Monograph section
| Field | Value |
|---|---|
| Drug | SKY-0515 |
| Indication reviewed | Huntington's disease |
| Therapeutic category | RNA splicing modulators |
| Manufacturer | Skyhawk Therapeutics |
| Regulatory status | Not approved in any country. Provisional approval application submitted to Australia's Therapeutic Goods Administration in March 2026 |
| Data as of | September 21, 2026 |
| Review status | Draft for pharmacy and therapeutics committee review |
Introduction
Disease background
Definition: progressive motor, cognitive, and psychiatric manifestations inherited in an autosomal dominant manner
United States prevalence: symptomatic population and claims-based estimates
“In the Medicare population, 1,941 prevalent and 819 incident cases of HD were identified in 2017, corresponding to a prevalence proportion of 13.1 per 100,000 persons and incidence rate of 6.1 per 100,000 person-years. In the Medicaid population, 353 prevalent cases of HD were identified in 2014, corresponding to a prevalence proportion of 15.2 per 100,000 persons.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
United States incidence: commercial insurance claims, 2003 to 2016
“Using an insurance database of over 67 million enrollees, we retrospectively identified a cohort of 3,707 individuals diagnosed with Huntington’s disease between 2003–2016.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We estimated a cumulative age-adjusted HD frequency rate of 6.52 per 100,000 persons and a cumulative incidence rate of 1.22 per 100,000 person years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Age at onset and prodromal phase
Survival after onset and age at death
Motor symptoms: chorea early and hypokinetic features later
Non-motor symptoms: functional impact, depression, and apathy
“Chorea and other aspects of the movement disorder are the most visible aspect of the disease. However, non-motor features have greatest affect on functional independence and quality of life, so require recognition and management.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Burden: health-related quality of life and healthcare costs by disease stage
“Mean HRQoL values declined across disease phases for the 84 participants; early phase (n = 34): mean = 0.84 (SD = 0.13), middle phase (n = 19): mean = 0.74 (SD = 0.10) and advanced phase (n = 31): mean = 0.65 (SD = 0.5).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We identified 3,688 matched pairs of beneficiaries with and without HD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Mean [SD] annual total healthcare costs were higher for HD beneficiaries than beneficiaries without HD ($41,631 [57,393] vs. $17,222 [31,218], p < .001) and were primarily driven by outpatient pharmacy costs ($19,182 [45,469] vs. $4,318 [11,553], p < .001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the stratified analysis, total healthcare costs were highest among beneficiaries with late-stage HD (mean [SD] cost: $20,475 [$41,122] for early-stage vs. $29,733 [$44,977] for middle-stage vs. $56,657 [$64,185] for late-stage; p < .001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Development and regulatory status
Australia: TGA provisional approval pathway eligibility and application submission
Australia: date of the application submitted to the TGA
Australia: duration of provisional registration
United States, Canada, and United Kingdom: clinical trial authorizations
FDA or EMA marketing application, orphan, fast track, breakthrough therapy, or PRIME designations
No evidence found.
Pharmacology and usage
Mechanism of action
HTT lowering through splicing modulation
Molecular mechanism: cryptic exon inclusion in HTT pre-mRNA
Target selectivity: independent commentary
Pharmacodynamics
Participants with HD: blood mHTT and total HTT protein through 12 months
Participants with HD: biomarker reductions through 15 months
Neurofilament light chain
CSF markers of neuroinflammation and neuronal injury
Pharmacokinetics
Participants with HD: dose proportionality and steady state
Terminal half-life, food effect results, metabolism, and renal excretion
No evidence found.
Indications
Current availability limited to clinical trials
Dosing and administration
| Drug | Available formulations | Route | Frequency studied | Comments |
|---|---|---|---|---|
| SKY-0515 | “9 mg tablets of SKY-0515” | “Oral” | “Once daily” | “Open label SKY-0515 will be self-administered daily (QD).” |
Dose strengths studied in participants with HD
Proposed commercial dose, dose adjustment, and administration with food
No evidence found.
Clinical efficacy summary
SKY-0515-001 part C
Design and population
Randomized placebo-controlled period followed by blinded active extension
HD-ISS stage criteria
Participants analyzed by timepoint and external control sizes
Baseline characteristics by extension dose group, mean ± SD
| Characteristic | SKY-0515 4 mg (n=7) | SKY-0515 9 mg (n=16) |
|---|---|---|
| Sex, % M/F | “57/43” | “38/62” |
| Age | “52.3 ± 8.8” | “57.8 ± 6.4” |
| CAG repeats | “42.4 ± 1.7” | “42.6 ± 2.1” |
| CAP score | “453.5 ± 64.4” | “510.2 ± 88.1” |
| cUHDRS | “12.1 ± 3.1” | “11.8 ± 2.3” |
| TFC | “11.4 ± 1.8” | “11.8 ± 1.7” |
Endpoints
Externally controlled cUHDRS analysis: designated primary timepoint
Efficacy results
Month 15 change from baseline versus overlap-weighted external control
| Endpoint | SKY-0515 LS mean (SE), Month 15 (n=15) | External control LS mean (SE), Month 15 | Difference | 95% CI | p-value |
|---|---|---|---|---|---|
| cUHDRS (composite) | “+0.94 (0.42)” | “-0.65 (0.27)” | “+1.59” | “1.09, 2.09” | “<0.001” |
| TFC | “+0.38 (0.43)” | “-0.60 (0.26)” | “+0.98” | “0.34, 1.61” | “0.003” |
| TMS | “-6.85 (1.02)” | “+2.53 (0.59)” | “-9.38” | “-11.58, -7.19” | “<0.001” |
| SDMT | “+4.63 (1.60)” | “+0.48 (0.98)” | “+4.15” | “1.04, 7.25” | “0.009” |
| SWRT | “+3.55 (1.62)” | “-0.63 (0.98)” | “+4.18” | “0.55, 7.80” | “0.024” |
cUHDRS change by timepoint versus overlap-weighted external control
| Timepoint | Treated LS mean (SE) | Treated participants | External control LS mean (SE) | Treatment difference | 95% CI | p-value |
|---|---|---|---|---|---|---|
| Month 3 | “+0.70 (0.30)” | “n=24” | “+0.05 (0.47)” | “+0.66” | “-0.33, 1.64” | “0.191” |
| Month 6 | “+0.47 (0.39)” | “n=20” | “-0.31 (0.21)” | “+0.78” | “0.00, 1.56” | “0.051” |
| Month 9 | “+0.70 (0.38)” | “n=20” | “-0.34 (0.23)” | “+1.04” | “0.39, 1.70” | “0.002” |
| Month 12 | “+0.29 (0.44)” | “n=18” | “-0.50 (0.26)” | “+0.79” | “0.11, 1.48” | “0.023” |
| Month 15 | “+0.94 (0.42)” | “n=15” | “-0.65 (0.27)” | “+1.59” | “1.09, 2.09” | “<0.001” |
Month 12 interim cUHDRS versus propensity score-weighted natural history: June 2026 poster
Pharmacodynamic results at day 84 and month 12
Clinician and Patient Global Impression at 12 months
Interpretation of global impression data: independent commentary
Limitations
External control limitation: independent commentary
SKY-0515-001 parts A and B
Design and population
Randomized, double-blind, placebo-controlled SAD and MAD
Key inclusion criteria
Dose ranges
Endpoints
No evidence found.
Efficacy results
Pharmacodynamic results: blood HTT mRNA
Limitations
No evidence found.
FALCON-HD 004-ANZ
Design and population
Phase 2/3 randomized, double-blind, placebo-controlled, dose-ranging design
Study periods and safety oversight
Key inclusion criteria
| Criterion | Quoted registry text |
|---|---|
| Age | “You must be 25 years or older.” |
| Genetic diagnosis | “You must have Huntington's Disease confirmed through genetic testing, with a specific gene change (CAG repeat of 40 or more).” |
| Function | “Total Functional Capacity (TFC) score of 10 or more).” |
| Motor signs | “Total Motor Score (TMS) of 6 or more).” |
| Independence | “Independence Score (IS) of 70 or more).” |
Key exclusion criteria
Treatment arms
| Arm | Quoted registry description |
|---|---|
| 1 (Active) | “Dosage Level(s): Low dose once daily oral” |
| 2 (Active) | “Dosage Level(s): Mid dose once daily oral” |
| 3 (Active) | “Dosage Level(s): High dose once daily oral” |
| 4 (Control) | “Matching placebo once daily oral” |
Endpoints
Registered primary outcomes
Efficacy results
No evidence found.
Limitations
No evidence found.
FALCON-HD 004-WW
Design and population
Phase 2/3 randomized, double-blind, placebo-controlled, dose-ranging design
Registered site countries
Key inclusion criteria
| Criterion | Quoted registry text |
|---|---|
| Age | “25 years or older.” |
| Genetic diagnosis | “Huntington's Disease confirmed through genetic testing, with a specific change in exon 1 of the HTT gene (CAG repeat of 40 or more).” |
| Function | “Total Functional Capacity (TFC) score of 10 or more).” |
| Motor signs | “Total Motor Score (TMS) of 6 or more).” |
| Independence | “Independence Score (IS) of 70 or more).” |
Planned enrollment: registry record
| Enrollment type | Participants |
|---|---|
| Estimated | “400” |
Planned enrollment: company statement of approximately 600 participants
Endpoints
Secondary outcomes
Efficacy results
No evidence found.
Limitations
No evidence found.
SKY-0515-008
Design and population
Study dates and countries
| Item | Registry record |
|---|---|
| Study start (actual) | “2026-04-10” |
| Primary completion (estimated) | “2029-12” |
| Countries | “Australia”· “New Zealand” |
Planned enrollment
| Enrollment type | Participants |
|---|---|
| Estimated | “500” |
Endpoints
Efficacy results
No evidence found.
Limitations
No evidence found.
Clinical guidelines
Guidelines predate SKY-0515 and describe no therapy that halts or slows progression
European Huntington's Disease Network guideline (2019): chorea, psychiatric symptoms, and multidisciplinary care
American Academy of Neurology evidence-based guideline (2012), retired in 2022: chorea and neuroleptics
“If HD chorea requires treatment, clinicians should prescribe tetrabenazine (up to 100 mg/day), amantadine (300-400 mg/day), or riluzole (200 mg/day) (Level B) for varying degrees of expected benefit. Occurrence of adverse events should be discussed and monitored, particularly depression/suicidality and parkinsonism with tetrabenazine and elevated liver enzymes with riluzole.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Data are insufficient to make recommendations regarding the use of neuroleptics or donepezil for HD chorea treatment (Level U).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
German Neurological Society guideline (2023): tiapride, tetrabenazine, psychiatric symptoms, and psychosocial interventions
“The quality of data from RCTs is currently best for VMAT2 inhibitors” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Because of the favorable profile of side effects, in particular with regard to extrapyramidal (akathisia, Parkinsonism) and behavioral (depression) symptoms, the consensus in the Delphi group was that tiapride should be considered as first line treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The use of tetrabenazine (in combination or as monotherapy) is recommended if treatment with tiapride is either not tolerated or not efficacious.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Comparative studies (comparing head-to-head compounds for their ability to suppress hyperkinesias short- and long-term) are unavailable.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There is hardly any data from RCTs or controlled studies on treating mental health problems in HD. Recommendations are therefore based on expert opinion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Symptom-based psychosocial interventions such as psychological procedures, occupational therapy, and physical activity are recommended to stabilize and maintain everyday functions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Movement Disorder Society evidence-based review (2022): interventions supported by eligible evidence
“These data supported a likely effect of deutetrabenazine on motor impairment, chorea, and dystonia and of tetrabenazine on chorea.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Data for therapeutic interventions in HD are limited and support only the use of VMAT2 inhibitors for specific motor symptoms.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“There was no eligible evidence to support the use of specific treatments for depression, psychosis, irritability, apathy, or suicidality.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Similarly, no evidence was eligible to support the use of physiotherapy, occupational therapy, exercise, dietary, or surgical treatments.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Huntington Study Group expert consensus (2026): medication classes used for chorea
“Despite the negative impact chorea can have on many aspects of day-to-day life, pharmacologic treatment remains underutilized in clinical practice.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The two most common medication classes used to suppress chorea are vesicular monoamine transporter 2 (VMAT2) inhibitors and antipsychotics.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Huntington's Disease Society of America physician's guide (2011): when to treat chorea, off-label neuroleptics, and antidepressants
Diagnostic confirmation and staging criteria that define the treated population
“The Huntington's Disease Integrated Staging System (HD-ISS) comprises a biological research definition and evidence-based staging centred on biological, clinical, and functional assessments.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“If there are signs of neurodegeneration, evidenced by atrophy of the caudate or putamen, individuals are assigned to stage 1. If disease signs are measurable by the TMS or Symbol Digit Modalities Test (SDMT), they are classified as stage 2. Finally, if there is an impact on daily functioning as assessed by the Total Functional Capacity (TFC) or the Independence Scale, individuals are assigned to stage 3.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Clinical motor diagnosis, or a Diagnostic Confidence Level (DCL) of 4, corresponds to the latter part of HD-ISS stage 2.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Safety summary
Contraindications
No approved labeling and therefore no labeled contraindications: SKY-0515 is not approved for use in any disease or in any country
Phase 2/3 exclusion criterion: psychiatric history
Boxed warning
No approved labeling and therefore no boxed warning: SKY-0515 is not approved for use in any disease or in any country
Warnings and precautions
No approved labeling and therefore no labeled warnings and precautions: SKY-0515 is not approved for use in any disease or in any country
Peripheral neuropathy monitoring in participants with Huntington's disease
Common adverse reactions
Most common related treatment-emergent adverse events in participants with Huntington's disease
Adverse event severity and distribution across treatment arms through month 9
Serious adverse events in the phase 1/2 trial
Adverse events in healthy participants in Parts A and B
Tolerability through fifteen months of treatment
Adverse event incidence by treatment arm and discontinuations due to adverse events
No evidence found.
Drug interactions
Protocol restriction: St. John’s Wort
Clinical drug interaction studies
No evidence found.
Special populations
Age ranges studied in the phase 1, phase 1/2, and phase 2/3 trials
| Study | Quoted criterion |
|---|---|
| Part C, participants with HD | “Males and females, aged between 25 and 70 years.” |
Renal and hepatic impairment: phase 1 exclusion criteria
Pregnancy, lactation, and contraception: phase 2/3 criteria
Pediatric and juvenile-onset HD, pharmacokinetics in renal or hepatic impairment
No evidence found.
Comparators and place in therapy
Approved symptomatic therapies for chorea: labeled indication, boxed warnings, and labeled adverse reaction rates
Approved symptomatic therapies for chorea: treatment effects in placebo-controlled trials
Comparisons among approved and off-label antichoreic agents
“Compared with tetrabenazine, deutetrabenazine was associated with a significantly lower risk of moderate to severe AEs and neuropsychiatric AEs including agitation, akathisia, depression, depression/agitated depression, drowsiness/somnolence, insomnia, and parkinsonism in both adjusted and unadjusted analyses (p < 0.05 for each).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There is low-quality evidence that tetrabenazine and deutetrabenazine do not differ in efficacy or safety.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We conducted a pragmatic, randomized, open-label trial across 11 centers of the French-Speaking Huntington's Network, enrolling 179 patients with Huntington's disease.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Tetrabenazine was most frequently associated with mood disorders and sedation, while olanzapine caused occasional weight gain and mild increases in LDL and total cholesterol.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Investigational disease-modifying candidates: differences in mechanism, route, and dosing
“Furthermore, the DMTs currently under development vary in mechanism of action (small molecule, ASO, gene therapy), route of administration (oral, intrathecal, intraparenchymal), and once vs recurrent therapy; these contingencies make it difficult at this time to assign a DMT price in our exploratory analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
AMT-130: administration, 36-month results versus external controls, and FDA position
“The prespecified analysis included 29 treated participants (17 high-dose, 12 low-dose), with 12 patients per cohort reaching 36 months of follow-up. Outcomes were compared with propensity score-matched external controls from the Enroll-HD natural history dataset (n = 940 for high dose; n = 626 for low dose). At 36 months, high-dose AMT-130 met the primary endpoint, demonstrating a statistically significant 75% slowing of disease progression versus controls, as measured by the cUHDRS” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Tominersen: phase 3 GENERATION HD1 design, discontinuation, and week 69 results
“in which 791 participants with manifest Huntington’s disease were randomly assigned in a 1:1:1 ratio to receive intrathecal tominersen, at a dose of 120 mg every 8 weeks or every 16 weeks, or placebo” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The primary end point was the change from baseline in the score on the composite Unified Huntington’s Disease Rating Scale (cUHDRS) or Total Functional Capacity (TFC) scale at week 101.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Biomarker end points included levels of mutant HTT in CSF, levels of neurofilament light protein (NfL) in CSF, and ventricular volume.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“On the basis of an overall benefit–risk assessment by an independent data monitoring committee, treatment was stopped in March 2021; therefore, an ad hoc analysis of the results at week 69 was carried out” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the every-8-week tominersen group, the mean change from baseline in the score on the cUHDRS at week 69 was significantly worse than that in the placebo group (−0.54 points, adjusted P=0.001), but the mean change from baseline in the score on the TFC scale did not differ significantly (−0.40 points, adjusted P=0.09).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the every-16-week tominersen group, the mean changes from baseline in the scores on the cUHDRS and the TFC scale did not differ significantly from those in the placebo group (−0.16 points, adjusted P=0.84; and −0.04, adjusted P=1.00, respectively)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Nonetheless, these results must be interpreted with caution, given the ad hoc nature of the analysis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“More adverse events occurred in the participants in the every-8-week tominersen group than in those in the placebo group and the every-16-week tominersen group” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“GENERATION HD2 is a phase II, randomised, double-blind, placebo-controlled, dose-finding clinical trial comparing 60 mg tominersen, 100 mg tominersen and placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The clinical trial remains ongoing, and definitive conclusions regarding clinical benefit will only be possible once the data are unblinded and fully analysed. This is anticipated to be late 2026.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Votoplam: oral splicing modifier results and comparability with the SKY-0515 dataset
“PTC518 (also known as votoplam), an orally administered huntingtin mRNA splice modulator.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The study met its primary endpoint, showing dose-dependent reductions in blood HTT protein levels at week 12, along with a favourable safety and tolerability profile across all dose levels and disease stages.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pridopidine: phase 3 PROOF-HD primary endpoint and CHMP opinion
“The primary and key secondary endpoints, change in total functional capacity (TFC) and composite Unified Huntington's Disease Rating Scale (cUHDRS) score at week 65, were not met in the overall population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Anticipated use and care setting for SKY-0515: studied population, oral administration, and specialist care
Direct head-to-head clinical comparison with votoplam, AMT-130, tominersen, WVE-003, or another active therapy
No evidence found.
Conclusion
No approved therapy alters the course of the disease
Strongest reported efficacy result: month 15 change from baseline versus overlap-weighted external control
| Endpoint | Treated LS mean (SE), M15 (n=15) | External control LS mean (SE), M15 | Treatment difference | 95% CI | p-value |
|---|---|---|---|---|---|
| cUHDRS (composite) | “+0.94 (0.42)” | “-0.65 (0.27)” | “+1.59” | “1.09, 2.09” | “<0.001” |
| TFC | “+0.38 (0.43)” | “-0.60 (0.26)” | “+0.98” | “0.34, 1.61” | “0.003” |
| TMS | “-6.85 (1.02)” | “+2.53 (0.59)” | “-9.38” | “-11.58, -7.19” | “<0.001” |
| SDMT | “+4.63 (1.60)” | “+0.48 (0.98)” | “+4.15” | “1.04, 7.25” | “0.009” |
| SWRT | “+3.55 (1.62)” | “-0.63 (0.98)” | “+4.18” | “0.55, 7.80” | “0.024” |
Constraint on that result: the comparison is against an external control, not a randomized placebo group
Safety statement carried by the program to date
Regulatory standing: eligibility for a provisional pathway is not an approval
References
- Ajitkumar et al. (2025) (opens in a new tab)
- American Academy of Neurology (2022) (opens in a new tab)
- ANZCTR ACTRN12623001161617 (opens in a new tab)
- ANZCTR ACTRN12624000602527 (opens in a new tab)
- Armstrong and Miyasaki (2012) (opens in a new tab)
- Bachoud-Lévi et al. (2019) (opens in a new tab)
- Bates et al. (2015) (opens in a new tab)
- Bruzelius et al. (2019) (opens in a new tab)
- Caldeira Brás et al. (2026) (opens in a new tab)
- Claassen et al. (2017) (opens in a new tab)
- ClinicalTrials.gov NCT06873334 (opens in a new tab)
- ClinicalTrials.gov NCT07378644 (opens in a new tab)
- ClinicalTrials.gov NCT07537075 (opens in a new tab)
- DailyMed AUSTEDO prescribing information (2025) (opens in a new tab)
- DailyMed INGREZZA prescribing information (2026) (opens in a new tab)
- DailyMed XENAZINE prescribing information (2019) (opens in a new tab)
- Exuzides et al. (2021) (opens in a new tab)
- Exuzides et al. (2022b) (opens in a new tab)
- Farag et al. (2026) (opens in a new tab)
- Ferreira et al. (2022) (opens in a new tab)
- Fox and Harding (2026) (opens in a new tab)
- Furr Stimming et al. (2026) (opens in a new tab)
- Guzauskas et al. (2024) (opens in a new tab)
- Harding (2025) (opens in a new tab)
- Harding (2026a) (opens in a new tab)
- Harding (2026b) (opens in a new tab)
- Hernandez (2026a) (opens in a new tab)
- Hernandez (2026b) (opens in a new tab)
- Huntington's Disease News (2026) (opens in a new tab)
- Huntington's Disease Society of America (2011) (opens in a new tab)
- Huntington's Disease Society of America (2020) (opens in a new tab)
- Huntington's Disease Society of America Centers of Excellence (opens in a new tab)
- McColgan et al. (2023) (opens in a new tab)
- Mestre et al. (2009b) (opens in a new tab)
- Miller et al. (2026a) (opens in a new tab)
- Miller et al. (2026b) (opens in a new tab)
- PTC Therapeutics (2026) (opens in a new tab)
- Reilmann et al. (2025) (opens in a new tab)
- Rodrigues et al. (2017a) (opens in a new tab)
- Saft et al. (2023) (opens in a new tab)
- Sampaio et al. (2024) (opens in a new tab)
- Skyhawk Therapeutics chief commercial officer announcement (2026) (opens in a new tab)
- Skyhawk Therapeutics community letter (2026) (opens in a new tab)
- Skyhawk Therapeutics FALCON-HD expansion announcement (2026) (opens in a new tab)
- Skyhawk Therapeutics fifteen-month results announcement (2026) (opens in a new tab)
- Skyhawk Therapeutics phase 1 topline results announcement (2024) (opens in a new tab)
- Skyhawk Therapeutics TGA eligibility announcement (2026) (opens in a new tab)
- Skyhawk Therapeutics twelve-month cUHDRS subcomponent announcement (2026) (opens in a new tab)
- Skyhawk Therapeutics twelve-month results announcement (2026) (opens in a new tab)
- Snowden (2017) (opens in a new tab)
- Tabrizi et al. (2022) (opens in a new tab)
- uniQure (2025) (opens in a new tab)
- uniQure BLA plan announcement (2026) (opens in a new tab)
- uniQure BLA submission announcement (2026) (opens in a new tab)
- uniQure regulatory update (2026) (opens in a new tab)
- van Walsem et al. (2022) (opens in a new tab)
- Youssov et al. (2025) (opens in a new tab)